Prevalence, treatments and medical cost of multiple sclerosis in Japan based on analysis of a health insurance claims database
ConclusionsUsing real‐world data, we obtained up‐to‐date prevalence, treatment status and medical cost information for MS in Japan. The present results showed the efficacy of a real‐world database to obtain the latest national trends for rare diseases, such as MS; this could have important implications for clinicians and policymakers.
Comparison of the medical costs per patient per month (PPPM, upper) and per member per month (PMPM, below) of multiple sclerosis with those of similar immune or neurodegenerative diseases in Japan. Although the cost PPPM for MS was higher than the costs for Parkinson's disease and rheumatoid arthritis, the cost PMPM for MS was lower than costs for these diseases due to the relatively low prevalence of MS in Japan.
Source: Clinical and Experimental Neuroimmunology - Category: Neurology Authors: Mieko Ogino, Shuichi Okamoto, Hiroyuki Ohta, Mariko Sakamoto, Yusuke Nakamura, Kosuke Iwasaki, Manami Yoshida, Shinzo Hiroi, Izumi Kawachi Tags: Original Article Source Type: research
More News: Arthritis | Brain | Databases & Libraries | Gilenya | Health Insurance | Insurance | Japan Health | Multiple Sclerosis | Myasthenia Gravis | Neurology | Parkinson's Disease | Rare Diseases | Rheumatoid Arthritis | Rheumatology